Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 17/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 7/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27182006 | 0.85 | CSNK2A1 (0.54) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27182012 | 0.83 | CSNK2A1 (0.62) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27182015 | 0.81 | CSNK2A1 (0.52) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27182013 | 0.80 | CSNK2A1 (0.51) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27182010 | 0.79 | CSNK2A1 (0.62) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27182009 | 0.78 | CSNK2A1 (0.64) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27182007 | 0.77 | CSNK2A1 (0.48) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27182008 | 0.76 | CSNK2A1 (0.65) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27074478 | 0.76 | CSNK2A1 (0.49) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27182016 | 0.76 | CSNK2A1 (0.66) | CSNK2A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970496-B1 | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-30 | — | — | US | claimed |
| US-11958851-B1 | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-16 | — | — | US | claimed |
| US-11945818-B1 | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-02 | — | — | US | claimed |
| US-11970496-B1 | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-30 | — | — | US | disclosed |
| US-11958851-B1 | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-16 | — | — | US | disclosed |
| US-11945818-B1 | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970496-B1 | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors | CSNK2A3, CSNK2A1, CSNK1G2 | CSNK2A1 2/4885EGFR 1750/4885KDR 1462/4885 |
| US-11945818-B1 | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors | CSNK2A3, CSNK2A1, CSNK2A2 | CSNK2A1 2/4885EGFR 2181/4885KDR 1755/4885 |
| US-11958851-B1 | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors | SKP2, CSNK2A3, CKS2 | CSNK2A1 6/4885EGFR 2261/4885KDR 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.